Current issue
Archive
Manuscripts accepted
About the Journal
Editorial office
Editorial board
Section Editors
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Most read articles
Instructions for authors
Article Processing Charge (APC)
Regulations of paying article processing charge (APC)
COMMENTARY
LDL-cholesterol control in high-risk individuals: an international obstacle and call for earlier combination lipid-lowering therapy
1
Emory Center for Heart Disease Prevention, Emory University School of Medicine, Atlanta, GA, USA
2
Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Submission date: 2025-05-21
Acceptance date: 2025-06-12
Online publication date: 2025-06-26
Corresponding author
Roger S. Blumenthal
MD, FACC, FAHA, FASPC Kenneth Jay Pollin Professor of Cardiology Director, Ciccarone Center for the Prevention of Cardiovascular Disease Johns Hopkins University School of Medicine 600 North Wolfe St Halsted 560 Baltimore, MD 21287, USA Phone: 410-955-7376
MD, FACC, FAHA, FASPC Kenneth Jay Pollin Professor of Cardiology Director, Ciccarone Center for the Prevention of Cardiovascular Disease Johns Hopkins University School of Medicine 600 North Wolfe St Halsted 560 Baltimore, MD 21287, USA Phone: 410-955-7376
TOPICS
REFERENCES (9)
1.
Chong B, Jayabaskaran J, Jauhari SM, et al. Global burden of cardiovascular diseases: projections from 2025 to 2050. Eur J Prev Cardiol 2024: zwae281. DOI: https://doi.org/10.1093/eurjpc....
2.
Toth S, Turek M, Pella D. Success in achieving LDL-C target values in a high-risk population in Slovakia: SlovakLipid retrospective study. Arch Med Sci 2023. https://doi.org/10.5114/aoms/1....
3.
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41: 111-88.
4.
Cannon CP, de Lemos JA, Rosenson RS, et al. Use of lipid-lowering therapies over 2 years in GOULD, a registry of patients with atherosclerotic cardiovascular disease in the US. JAMA Cardiol 2021; 6: 1060.
5.
Baum SJ, Rane PB, Nunna S, et al. Geographic variations in lipid-lowering therapy utilization, LDL-C levels, and proportion retrospectively meeting the ACC/AHA very high-risk criteria in a real-world population of patients with major atherosclerotic cardiovascular disease events in the United States. Am J Prev Cardiol 2021; 6: 100177.
6.
Ray KK, Molemans B, Schoonen WM, et al. EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study. Eur J Prev Cardiol 2021; 28: 1279-89.
7.
Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387-97.
8.
Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376: 1713-22.
9.
Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018; 379: 2097-107.
| eISSN: | 1896-9151 |
| ISSN: | 1734-1922 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
